And from 2002 to 2012, he worked at Danaher Corporation in a variety of roles in General Management and M&A/Business Development.

From 2012 to 2015, he was SVP of Strategy and Business Development at Pall Corporation. He joined Milliken in 2015 initially as EVP of Corporate Strategy and Corporate Development. Prior to joining Standard BioTools, Alex was President of Milliken’s Healthcare Division, a leading provider of advanced wound care products for human health, animal health, and sports medicine. Alex has a passion for improving healthcare and in building businesses by bringing together teams and capabilities to accelerate the pace of innovative breakthroughs. He has published more than 100 research papers, with several in the most prestigious peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine.ĭuring his personal time, Michael is an avid runner, yogi, scuba diver and an instrument-rated private pilot.Īlex Kim is Chief Operating Officer of Standard BioTools. More than 2,300 peer-reviewed papers have been published on the properties and uses of PNA, including 42 authored by Michael. While a research associate at the University of Copenhagen, he was lead inventor of peptide nucleic acids (PNA) technology, a synthetic form of DNA, for which he earned his PhD in organic chemistry. There, he spearheaded several large, high-profile programs, including the Neanderthal Sequencing project and the sequencing of the first individual human genome.Īn elected member of the Royal Danish Academy of Sciences and Letters, Michael is the named inventor of 40 U.S. Prior to Danaher, Michael was the Chief Technology Officer at Roche’s 454 Life Sciences Corporation, the first company to successfully commercialize next-generation sequencing. During that time, he led Danaher’s Pall Corporation Biopharmaceutical business where he played a central role in redesigning its go-to-market structure, leading to the company’s multibillion-dollar revenue today. Prior to joining Standard BioTools, he served as the Chief Technology Officer of Danaher Life Sciences as well as the founder and leader of Danaher’s corporate venture fund.

Michael brings more than 25 years of proven leadership in developing and commercializing innovative technologies that drive success in the discovery and development of biopharmaceuticals. Under his direction, Standard BioTools is expected to grow into a best-in-class solutions partner to biopharmaceutical researchers through the expansion of in-house technologies and future acquisitions.

Michael Egholm leads Standard BioTools in its mission to unleash its next-generation technologies to help drive innovation in the life science industry. As President and Chief Executive Officer, Dr.

Key product chief architect x9